A new vaccine against tick-borne encephalitis: initial trial in man including a dose-response study.
A new vaccine against tick-borne encephalitis was investigated in 56 healthy volunteers randomized for five different doses of antigen in a comparative group trial. Good tolerability and high immunogenicity were found using three different antibody test systems. The dose response study revealed that there was a strong relationship between the amount of antigen administered and the antibody response over the range of 0.03-3.0 micrograms antigen per dose.
Bock
H L
HL
Smith Kline Dauelsberg GmbH, Clinical Research, München, FRG.
Klockmann
U
U
Jüngst
C
C
Schindel-Künzel
F
F
Theobald
K
K
Zerban
R
R
D000328:Adult; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D002642:Chick Embryo; D004306:Dose-Response Relationship, Immunologic; D004669:Encephalitis Viruses, Tick-Borne / Q000276:immunology*; D004675:Encephalitis, Tick-Borne / Q000517:prevention & control*; D004797:Enzyme-Linked Immunosorbent Assay; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D011897:Random Allocation; D015164:Vaccines, Inactivated / Q000009:adverse effects / Q000276:immunology; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology*
D000914:Antibodies, Viral; D015164:Vaccines, Inactivated; D014765:Viral Vaccines